TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription infusion that treats certain forms of breast cancer in adults. Learn about dosage, side effects, and more.

Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain types of breast cancer in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea ...

Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate. The ASCENT-03 study is a global, open-label, randomized phase III trial evaluating the efficacy and safety of Trodelvy ...

Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...

Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.

Trodelvy plus Keytruda significantly improves progression-free survival in metastatic triple-negative breast cancer expressing PD-L1 compared to Keytruda and chemotherapy. The safety profile of the ...

These findings support the expectation that Trodelvy combined with Keytruda will become the new SOC in PD-L1-positive TNBC, shifting the frontline treatment paradigm from chemoimmunotherapy to ADC ...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer ...

Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months. FOSTER CITY, Calif., May 31, 2025--Gilead Sciences, Inc. ...